We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01391637
First Posted: July 12, 2011
Last Update Posted: May 13, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
StemCells, Inc.
July 6, 2011
July 12, 2011
May 13, 2016
June 2011
March 2016   (Final data collection date for primary outcome measure)
Incidence of serious adverse events (SAEs), results of physical and neurological examination, laboratory tests and vital signs. [ Time Frame: 4 years ]
Same as current
Complete list of historical versions of study NCT01391637 on ClinicalTrials.gov Archive Site
  • Preliminary efficacy using Bayley-III and Callier-Azusa Scale. [ Time Frame: 4 years ]
    Changes compared to baseline
  • Changes in brain magnetic resonance imaging (MRI), electroencephalogram (EEG), seizure frequency and somato-sensory evoked potentials (SSEP). [ Time Frame: 4 years ]
    Changes compared to baseline
Same as current
Not Provided
Not Provided
 
Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)
Long-Term Follow-Up Safety and Preliminary Efficacy Study of Human Central Nervous System Stem Cell (HuCNS-SC®) Transplantation in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)
The purpose of this study is to determine the long term safety and preliminary effect of HuCNS-SC cells transplanted in subjects with Connatal Pelizaeus-Merzbacher Disease (PMD).

Only subjects who underwent HuCNS-SC transplantation under Protocol CL-N01-PMD will be enrolled in this long term follow-up study.

Subjects will return to the site six months and one year after completion of the Phase I study and then annually for a total study duration of four years. Phone calls will also be made by the Investigator to the subject's parent/legal guardian bi-annually to conduct a phone visit through the four-year duration of the study.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
PMD Subjects who underwent transplantation of HuCNS-SC cells under CL-N01-PMD study
  • Pelizaeus-Merzbacher Disease
  • PMD
Biological: HuCNS-SC transplant in the lead-in phase
Long-term safety follow-up study
HuCNS-SC transplanted subjects in the lead-in phase
Subjects who had HuCNS-SC transplant in the lead-in phase study CL-N01-PMD
Intervention: Biological: HuCNS-SC transplant in the lead-in phase
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4
March 2016
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who received HuCNS-SC cells under Protocol CL-N01-PMD

Exclusion Criteria:

  • Subjects who received off-protocol immunosuppressive medications.
  • Subjects who are concurrently enrolled in another investigational study.
Sexes Eligible for Study: Male
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01391637
CL-N02-PMD
No
Not Provided
Not Provided
StemCells, Inc.
StemCells, Inc.
Not Provided
Study Director: Stephen Huhn, MD StemCells, Inc.
StemCells, Inc.
May 2016